Answers are grounded in this paper and cite their sources.
The human microbiome contributes to immune regulation, metabolic homeostasis, epithelial barrier integrity, and inter-organ communication. This review integrates evidence from gut, oral, skin, and cervicovaginal microbiomes, focusing on epithelial barrier dysfunction, altered microbial metabolite signaling, innate immune activation, inflammatory signaling, immune dysregulation, and host-microbe interactions across non-communicable diseases and microbiome-based therapeutic approaches in these contexts. Collectively, current evidence suggests that dysbiosis may represent not only a disease-associated microbial signature but also a potential mechanistic contributor to disease development and progression, although substantial interindividual and disease-specific variability remains. Microbiome-based diagnostics, fecal microbiota transplantation, personalized nutrition, and microbial therapeutics show considerable translational potential; nevertheless, causal relationships and clinical efficacy remain insufficiently established for several applications. Future research should therefore prioritize rigorously designed interventional and longitudinal studies integrating multi-omics profiling with host genetics and immune phenotyping to establish causal mechanisms, identify reproducible biomarkers, and support the development of precision microbiome-based therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Ganguly et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: